A new pill, tavapadon, has shown potential in easing Parkinson’s symptoms while limiting side effects. In patients taking at ...

DelveInsight’s analysis forecasts Parkinson’s disease market growth due to the introduction of emerging therapies, expecting a rise in market size during the study period (2020–2034). The anticipated ...

In a small study, researchers transplanted stem cells into the brains of 12 Parkinson’s patients, stopping progression and ...

For patients with Parkinson's disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist ...

Parkinson’s Disease is a neurodegenerative disorder that affected predominately the Dopamine-producing neurons in a specific ...

Significant reduction also seen in change from baseline in daily OFF times vs placebo. HealthDay News — For patients with Parkinson disease with motor fluctuations, the oral once-daily ...

Lip twitching may not always be serious, but when it's persistent or paired with other symptoms, it deserves medical ...

The highly selective partial agonist at D1 and D5 receptors significantly improves motor function in patients recently ...

In a first-of-its-kind human trial, researchers transplanted iPS-cell-derived dopaminergic progenitors into patients with ...

Until now, levodopa has been the standard first-line treatment for Parkinson’s patients. Levodopa — which is converted into dopamine in the brain and targets the D2/D3/D4 dopamine receptors ...